HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FeBelGen gets rebrand and moves into OTC

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

FeBelGen, the Belgian off-patent medicines association, has been relaunched with a new name and a broader remit under the banner of Medaxes. As well as generic and biosimilar medicines, the association will represent the OTC industry, including self-medication, self-care medical devices and food supplements.

You may also be interested in...



US FDA Wants To Improve Communication, Education On Supplements, Cosmetics

Supplement industry stakeholders say proposal could reveal helpful information about consumers’ regard for VMS products. But until the questions FDA will ask in interviews are known, it’s not clear whether the information collection might sow doubt about the products.

Surveillance Data: The Key To Tackling AMR In Africa

A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.

Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma

Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Topics

UsernamePublicRestriction

Register

LL1132547

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel